





**[1,2,4]-TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVE****Publication number:** WO2004029056**Publication date:** 2004-04-08**Inventor:** IIDA KYOICHIRO (JP); SUGITA TAKAMASA (JP); SHIOZAKI SHIZUO (JP); KANDA TOMOYUKI (JP); KUWANA YOSHIHISA (JP); SHIMADA JUNICHI (JP)**Applicant:** KYOWA HAKKO KOGYO KK (JP); IIDA KYOICHIRO (JP); SUGITA TAKAMASA (JP); SHIOZAKI SHIZUO (JP); KANDA TOMOYUKI (JP); KUWANA YOSHIHISA (JP); SHIMADA JUNICHI (JP)**Classification:**

**- International:** A61P9/00; A61P9/10; A61P21/00; A61P25/00; A61P25/14; A61P25/16; A61P25/20; A61P25/24; A61P25/28; A61P43/00; C07D487/04; C07D519/00; A61P9/00; A61P21/00; A61P25/00; A61P43/00; C07D487/00; C07D519/00; (IPC1-7): C07D487/04; A61K31/519; A61K31/5377; A61K31/55; A61K31/553; A61P9/00; A61P9/10; A61P21/00; A61P25/00; A61P25/14; A61P25/16; A61P25/20; A61P25/24; A61P25/28; A61P43/00

**- European:** C07D487/04; C07D519/00

**Application number:** WO2003JP12158 20030924**Priority number(s):** JP20020276896 20020924; JP20030139994 20030519**Also published as:**

 EP1544200 (A1)  
 US2006058320 (A1)  
 CA2500228 (A1)  
 AU2003272886 (A1)

**Cited documents:**

 WO9503806  
 EP0459702  
 EP0515107  
 WO9842711  
 WO0017201  
 WO03068776  
 XP002974911  
less <<

**Report a data error here****Abstract of WO2004029056**

A [1,2,4]-triazolo[1,5-c]pyrimidine derivative represented by the general formula (I): (I) (wherein R<1> represents (un)substituted aryl or an (un)substituted aromatic heterocyclic group; R<2> represents hydrogen, halogeno, lower alkyl, lower alkanoyl, aroyl, (un)substituted aryl, or an (un)substituted aromatic heterocyclic group; R<3> represents lower alkyl, lower cycloalkyl, (un)substituted lower alkanoyl, (un)substituted aryl, an (un)substituted aromatic heterocyclic group, etc.; and Q represents hydrogen or 3,4-dimethoxybenzyl) or a pharmacologically acceptable salt of the derivative. They have antiagonistic activity on an adenosine A2A receptor and are useful for treatments for and/or prevention of diseases attributable to adenosine A2A receptor hyperenergia.

---

Data supplied from the *esp@cenet* database - Worldwide